VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
On February26, 2019, VIVUS,Inc., or the Company, conducted a conference call during which members of its senior management team discussed financial results for the fourth quarter and year ended December31, 2018, a business update and certain other information. A copy of the transcript of the conference call is furnished herewith as Exhibit99.1.
The information in this Form8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
VIVUS INC Exhibit
EX-99.1 2 a19-5656_1ex99d1.htm EX-99.1 Exhibit 99.1 VIVUS,…
To view the full exhibit click here
About VIVUS,INC. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
